<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085665</url>
  </required_header>
  <id_info>
    <org_study_id>201909003(2)</org_study_id>
    <nct_id>NCT05085665</nct_id>
  </id_info>
  <brief_title>Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events</brief_title>
  <official_title>Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche sur les Filarioses et autres Maladies Tropicales (CRFilMT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine which Loa loa antigens are released into circulation when&#xD;
      infected individuals are treated with ivermectin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cohort of up to 50 participants with Loa loa microfilarial levels between 5,000 and 18,000&#xD;
      per ml/blood will be treated with ivermectin in an inpatient setting. Participants will be&#xD;
      monitored for treatment-related adverse events for seven days post-treatment, and will have&#xD;
      blood drawn on days 0, 1, 2, 3, and 7 post-treatment to assess for microfilarial load,&#xD;
      cytokine, and antigen levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cross-reactive antigenemia</measure>
    <time_frame>7 days</time_frame>
    <description>detection of Loa loa antigens in sera that cross-react with diagnostic tests for lymphatic filariasis</description>
  </primary_outcome>
  <enrollment type="Actual">39</enrollment>
  <condition>Loiasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>single dose, 150 ug/kg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Loa loa blood microfilariae of between 5,000 - 18,000 per mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergy to ivermectin; severe comorbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre de Recherche sur les Filarioses et autres Maladies Tropicales (CRFilMT)</name>
      <address>
        <city>Yaound√©</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

